Trial intelligence / Profile preview

Phase III randomized placebo-controlled trial of amenamevir patient-initiated therapy for recurrent genital herpes

jRCT2080224871Phase 3Completed

Sponsor
Maruho Co., Ltd.
Start
Sep 2019
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in genital herpes comparing Amenamevir with Placebo (vehicle) (2 arms). Primary endpoint: Time to complete lesion healing. Started Sep 2019; status: completed.

02

Drugs

Amenamevir
03

Conditions

genital herpes

Beyond the preview

Go deeper on jRCT2080224871.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT2080224871.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call